AZD4820 / AstraZeneca - LARVOL DELTA

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12. (PubMed, Mol Ther Oncol) - "AZD4820 treatment combined with anti-PD-L1 blocking antibody augmented tumor-specific T cell immunity relative to monotherapies. These findings suggest that vaccinia virus delivery of IL-12, combined with immune checkpoint blockade, elicits antitumor immunity in tumors that respond poorly to immune checkpoint inhibitors."

IO biomarker • Journal • Oncolytic virus • Oncology • IFNG • IL12A

AZD-4820, a new oncolytic virus for cancer (Bioworld) - "AZD-4820 was evaluated in a cell viability assay performed in 30 human cancer cell lines, defining 12 different types of cancer, and testing a dose-range of multiplicity of infection (MOI); potent oncolytic activity was observed with EC50 values of <0.1 MOI in nearly all of the tested cells."

Preclinical • Oncology • Solid Tumor

AZD4820 Oncolytic Vaccinia Virus Encoding IL-12 Mediates Anti-tumor Activity Through Oncolysis and Tumor-specific Immunity (SITC 2022) - "Conclusions AZD4820 is an oncolytic VACV expressing IL-12 in vitro and in vivo which replicates preferentially in tumor cells compared to normal cells. A surrogate of AZD4820 demonstrated activity in pre-clinical syngeneic mouse tumor models in combination with anti-PD-L1 mAb, supporting its use in combination with ICIs in patients with cancer."

Oncolytic virus • Oncology • IFNG • IL12A